Department of Neonatology, Sisli Etfal Training and Research Hospital, Istanbul, Turkey.
Department of Pediatrics, Tinaztepe University Faculty of Medicine, Izmir, Turkey.
J Int Med Res. 2020 Dec;48(12):300060520977442. doi: 10.1177/0300060520977442.
This study aimed to evaluate the significance of urinary kidney injury molecule-1 (uKIM-1) levels in predicting acute kidney injury (AKI) and mortality in very low birth weight (VLBW) preterm infants.
This prospective, observational cohort study was conducted on 39 VLBW preterm infants. Serum creatinine (SCr) and uKIM-1 levels were measured in the first 24 and 48 to 72 hours of life. The estimated glomerular filtration rate (eGFR) was calculated. Levels of uKIM-1 were measured with an enzyme-linked immunosorbent assay.
Among 39 VLBW infants, 9 (23%) developed AKI. The mortality rate was 17.9% (n = 7 neonates). There was no significant difference in SCr levels, uKIM-1 levels, or the eGFR obtained in the first 24 hours in the AKI group compared with controls. However, significant differences were found in SCr and uKIM-1 levels, and the eGFR rate at 48 to 72 hours between the groups. Levels of uKIM-1 were significantly higher in non-survivors than in survivors in the first 24 and 48 to 72 hours of life.
The level of uKIM-1 can be used as a simple noninvasive diagnostic method for predicting AKI and mortality, especially within 48 to 72 hours of life. We do not have a clinical trial registration ID. In Turkey, clinical trial registration is not required for non-drug, noninvasive, clinical studies.
本研究旨在评估尿肾损伤分子-1(uKIM-1)水平在预测极低出生体重(VLBW)早产儿急性肾损伤(AKI)和死亡率中的意义。
这是一项前瞻性观察队列研究,共纳入 39 例 VLBW 早产儿。在生后 24 小时和 48 至 72 小时内测量血清肌酐(SCr)和 uKIM-1 水平,并计算估计肾小球滤过率(eGFR)。采用酶联免疫吸附试验测定 uKIM-1 水平。
在 39 例 VLBW 婴儿中,9 例(23%)发生 AKI。死亡率为 17.9%(n=7 例新生儿)。AKI 组与对照组相比,在 24 小时内 SCr 水平、uKIM-1 水平和 eGFR 无显著差异。然而,在 48 至 72 小时时,两组间的 SCr 和 uKIM-1 水平以及 eGFR 率有显著差异。在生后 24 小时和 48 至 72 小时内,非幸存者的 uKIM-1 水平明显高于幸存者。
uKIM-1 水平可作为预测 AKI 和死亡率的简单非侵入性诊断方法,尤其是在生后 48 至 72 小时内。我们没有临床试验注册号。在土耳其,非药物、非侵入性的临床研究不需要进行临床试验注册。